Andrei Thomas-Tikhonenko Laboratory
Researchers at the Center for Childhood Cancer Research are investigating the molecular mechanisms behind the loss of the CD19 epitope after CART19 therapy.
Researchers are developing and evaluating chimeric antigen receptor (CAR)-modified T-cells to treat children with acute lymphoblastic leukemia (ALL).
Studies are underway to develop molecular tests that can help to preselect patients who are likely to respond to specific cancer therapeutics based on epistatic profiling of their tumor types.
Researchers discovered that thrombospondin-1 is an essential target of the MYC - miR-17-92 axis, and that this targeting drives tumor angiogenesis.
Elucidating the roles that E2F transcription factors play in cancer biology will help identify potential targets for therapeutic intervention.
Studies are currently underway to more clearly define the relationship between Myc-induced deregulation of miR-17-92 and BCR signaling.
Researchers demonstrated that in solid tumors, such as pediatric neuroblastoma and colon adenocarcinoma, deregulation of miR-17-92 leads to profound suppression of TGFβ signaling and diminished production of many anti-angiogenic TGFβ-inducible factors such as thrombospondin-1, CTGF, and clusterin.